Patient Beliefs That Affect Treatment Adherence and PA Outcomes
The 83% conversion gap starts in the exam room — navigate the five most common patient objections to migraine medication, and document each conversation to protect the PA narrative.
PA impact: This card directly affects prior authorization outcomes. Documentation language from this card can be used in PA letters and appeals.
Why this card exists
The 83% conversion gap — clinicians prescribing acute migraine treatments but never adopting preventive therapies — doesn't start at the PA submission. It starts in the exam room. Patient ambivalence about medication, misinformation absorbed from popular culture, and internalized beliefs about what migraine "should" be manageable with all affect whether a prescription gets written, filled, and continued.
A clinician who can navigate these conversations confidently is more likely to prescribe. And prescribing is the prerequisite for the PA.
"I don't want to be dependent on medication"
Clinical response: Migraine prevention is not symptom suppression — it's reducing the frequency of a neurological event. CGRP mAbs are not habit-forming, do not cause withdrawal, and can be discontinued at any time without rebound. The monthly or quarterly dosing schedule is comparable to a vaccine, not a daily dependency.
PA consequence: If the patient declines preventive therapy and the clinician doesn't document the conversation, the payer sees no evidence of disease severity. Document: "Discussed preventive therapy options. Patient expressed preference for non-pharmacological management. Counseled on disease progression risk with untreated high-frequency migraine. Will reassess at follow-up."
"I should be able to control this with diet/exercise/stress management"
Clinical response: Lifestyle modification is Level B–C evidence and appropriate as complementary therapy. It is not adequate as monotherapy for moderate-to-severe migraine. The prodrome/trigger distinction (see Card 15) is clinically relevant — many "triggers" are prodromal symptoms.
PA consequence: A note saying "recommended lifestyle modification" without clarifying it's complementary weakens the PA. Document: "Patient currently pursuing behavioral/lifestyle interventions as complementary therapy. Pharmacological prevention remains indicated based on [frequency] headache days per month and [severity] functional impact."
"The medication didn't work" (after one dose or sub-therapeutic trial)
Clinical response: Distinguish genuine treatment failure from inadequate trial. One dose of sumatriptan that didn't achieve pain freedom may mean wrong timing, wrong dose, wrong formulation, or expected side effects mistaken for treatment failure (see Card 16).
PA consequence: A genuinely failed adequate trial strengthens the PA. An inadequately documented "failure" can be challenged on appeal. Document with specifics: agent, dose, timing, number of attempts, and specific reason. "Sumatriptan 100mg failed to achieve pain freedom at two hours on three separate occasions with early treatment" is defensible. "Tried sumatriptan, didn't tolerate" is not.
"I read that [CGRPs cause heart problems / Botox is dangerous / triptans cause strokes]"
CGRP mAbs: No cardiovascular safety signal in clinical trials or post-marketing surveillance across millions of doses. The evidence base is reassuring.
Botox: OnabotulinumtoxinA at PREEMPT protocol doses (155 units) has decades of safety data. Cosmetic Botox concerns relate to off-protocol use, not standardized medical application.
Triptans: Contraindicated in established cardiovascular disease. In patients without cardiovascular disease — the prescribing population — no evidence of triptans causing cardiovascular events. Chest tightness is a non-cardiac triptan sensation, not a cardiac event (see Card 16).
"My headaches aren't bad enough for serious medication"
Clinical response: This is the most consequential belief for the treatment gap. Migraine disability is poorly correlated with perceived severity — patients normalize extraordinary levels of dysfunction. A patient who has restructured their entire life around avoiding triggers may be more disabled than a patient who reports severe pain but has fewer attacks.
The HV-FIS data from patient engagement provides an objective anchor: "Your data shows [X] days per month with significant functional limitation. That qualifies as [episodic/chronic] migraine and meets clinical criteria for preventive therapy."
PA consequence: The clinician who agrees that migraines "aren't that bad" doesn't prescribe. The clinician who reframes using functional impact data opens the door to appropriate treatment — and to the PA.
Ready to run a PA?
The PA Engine applies this guidance automatically — paste a clinical note and get a complete, payer-specific PA letter in under a minute. Free, no account required.
Run a PA — free →Citations: Lipton RB, et al. Neurology 2007;68(5):343-349 | Buse DC, et al. Neurology 2019;92(4):e349-e360 | Headache Vault Treatment Gap Analysis — 83% conversion gap (CMS Medicare Part D, 2024) | AHS Consensus 2021 — Ailani J et al., Headache 2021;61(7):1021-1039.